Ceapro Inc. to Present at NobleCon17
January 14, 2021 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 08, 2021 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 27, 2020 09:00 ET
|
Ceapro Inc.
– R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 – – Q3 2020 sales of $3,476,000...
Ceapro Inc. Announces Increased Financial Contribution from National Research Council of Canada for Innovative PGX Technology Project
October 22, 2020 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 14, 2020 08:35 ET
|
Ceapro Inc.
EDMONTON, Alberta, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports 2020 Second Quarter and Six-Month Financial Results and Operational Highlights
August 20, 2020 09:05 ET
|
Ceapro Inc.
– Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Company’s history – – R&D activities focused...
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic for COVID-19
August 18, 2020 08:05 ET
|
Ceapro Inc.
– First milestone successfully achieved in early stages of the ongoing research project with McMaster University – Confirmed capability of PGX Technology to optimize and standardize the size and...
Ceapro Inc. Announces Publication of Positive Results from Study Evaluating Avenanthramides in Exercise-Induced Inflammation
August 04, 2020 09:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Announces Results of 2020 Shareholders’ Meeting
June 22, 2020 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, June 22, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces Publication of Positive Results for a PGX Processed Drug Delivery System for Accelerated Burn Wound Healing
June 15, 2020 08:35 ET
|
Ceapro Inc.
– Results from successful drug-impregnation of PGX liquid processed alginate hydrogel scaffolds further bolsters Ceapro’s efforts to develop innovative delivery systems composed of new chemical...